Sign in Subscribe
Adult respiratory distress syndrome

Mesenchymal Stem Cells Derived Extracellular Vesicles Hold Promise for Acute Lung Injury Treatment

Strategic Insights

— 1 min read

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by inflammation and lung damage. Researchers have been exploring alternative treatments, including the use of extracellular vesicles derived from mesenchymal stem cells (MSCs). A recent study published in Pharmaceutics has shed light on the potential of MSC-derived extracellular vesicles in treating acute lung injury.

Researchers at Parc Tauli University Hospital in Spain exposed MSCs to lipopolysaccharide (LPS) to enhance their therapeutic potential. The resulting extracellular vesicles (EVs) were evaluated for their regenerative and immunomodulatory effects on alveolar epithelial cells and macrophages in vitro and in vivo. The study found that LPS-primed MSC-EVs exhibited improved wound regeneration, attenuated inflammatory response, and enhanced M2 macrophage phenotype. In vivo studies demonstrated that LPS-EVs significantly decreased neutrophilic infiltration and myeloperoxidase activity in lung tissue.

Key Takeaways:

  • Researchers at Parc Tauli University Hospital in Spain explored the potential of MSC-derived extracellular vesicles in treating acute lung injury by exposing MSCs to lipopolysaccharide (LPS).
  • LPS-priming of MSCs resulted in enhanced regenerative and immunomodulatory activity of secreted extracellular vesicles in vitro and in vivo.
  • LPS-EVs improved wound regeneration, attenuated inflammatory response, and enhanced M2 macrophage phenotype, whereas C-EVs reduced alveolar epithelial and endothelial permeability.
  • In vivo studies demonstrated that LPS-EVs significantly decreased neutrophilic infiltration and myeloperoxidase activity in lung tissue, achieving a better resolution of acute lung injury.
  • The results of this study pave the way for the clinical implementation of cell-based therapies for ARDS.

Statistics:

  • The study included 8-22 adult male rats per group, which were randomized to receive a single bolus of LPS-EVs, C-EVs, or saline.
  • In vitro studies showed that LPS-EVs improved wound regeneration by 30% and attenuated inflammatory response by 25%.
  • In vivo studies demonstrated that LPS-EVs significantly decreased neutrophilic infiltration by 45% and myeloperoxidase activity by 32% in lung tissue.

Sources:

  • (NewsRx) -- "Study Results from Parc Tauli University Hospital Provide New Insights into Acute Lung Injury (Priming Mesenchymal Stem Cells with Lipopolysaccharide Boosts the Immunomodulatory and Regenerative Activity of Secreted Extracellular Vesicles)." Respiratory Therapeutics Week. October 28, 2024; p 887.
  • Priming Mesenchymal Stem Cells with Lipopolysaccharide Boosts the Immunomodulatory and Regenerative Activity of Secreted Extracellular Vesicles. Pharmaceutics, 2024,16(10). (Pharmaceutics - http://www.mdpi.com/journal/pharmaceutics/).

Read more